Showing 3051-3060 of 3437 results for "".
- NRS Roundtable: Greater Focus on Facial Erythema in Rosacea Warrantedhttps://practicaldermatology.com/news/nrs-roundtable-greater-focus-on-facial-erythema-in-rosacea-warrated/2460392/Dermatologists should place greater emphasis on addressing persistent facial erythema in roscaea, according to experts at a recent National Rosacea Society (NRS) roundtable. Drawing from current scientific knowledge as well as clinical experience, the new standard classification of rosa
- Med Spas May Need a Post-COVID-19 Facelifthttps://practicaldermatology.com/news/medspas-may-need-a-post-covid-19-facelift/2460370/Everyone is feeling anxious about returning to public spaces including spas following the COVID-19 pandemic, according to the new ISPA Consumer Snapshot Initiative. “We know that COVID-19 has created a lot of uncertainty in many industries, including the spa industry,” says
- AAD Elects New Officers, Board Membershttps://practicaldermatology.com/news/aad-elects-new-officers-board-members/2460358/Mark D. Kaufmann, MD, FAAD, has been elected to lead the American Academy of Dermatology. He will be installed as president-elect in March 2021 and hold the office of president for one year beginning in March 2022. Dr. Kaufmann, who is a member of the Practical Dermatology®
- CSF Live Virtual Meeting to Assess SBA Loans: Tonighthttps://practicaldermatology.com/news/csf-live-virtual-meeting-to-access-sba-loans-tonight/2460334/As dermatology business owners’ heads are swimming trying to figure out the SBA loan to keep afloat during the COVID crisis, CSF, along with George Hruza, MD, immediate past-president of the AAD, and Greg Morganroth, MD, CEO and Founder of California Skin Institute, will discuss the ins-and
- Owing to the Advent of New Treatments, Melanoma Death Rates Drophttps://practicaldermatology.com/news/owing-to-the-advent-of-new-treatments-melanoma-death-rates-drop/2460312/Melanoma is killing the fewest Americans in decades, according to a study in the American Journal of Public Health. Death rates for metastatic melanoma among white Americans climbed 7.5 percent between 1986 and 2013, but then dropped by nearly 18 percent over the next thre
- Viper Equity Partners Seeks to Expand into Florida and Georgia Dermatology Marketshttps://practicaldermatology.com/news/viper-equity-partners-seeks-to-expand-into-florida-and-georgia-dermatology-markets/2460303/Viper Equity Partners is turning its attention to key dermatology and related aesthetics offices in Florida and Georgia to join private equity-backed partnerships. In an effort spearheaded by Senior Vice President Nina Das (see photo), the North Palm Beach-based M&A advisory firm is
- FDA Accepts NDA for Almirall's AK Drug Tirbanibulinhttps://practicaldermatology.com/news/fda-accepts-nda-for-almiralls-ak-drug-tirbanibulin/2460299/The FDA has reviewed and accepted the New Drug Application (NDA) from Almirall, SA for tirbanibulin, also known as ALM14789, for the treatment of actinic keratosis (AK). The FDA also communicated that it is not currently planning on holding an advisory committee to discuss the application. <
- Cold Plasma Patch May Make Immunotherapy More Effective for Treating Melanomahttps://practicaldermatology.com/news/cold-plasma-patch-may-make-immunotherapy-more-effective-for-treating-melanoma/2460275/A new medicated patch that can deliver immune checkpoint inhibitors and cold plasma directly to tumors may help boost the immune response and kill cancer cells, according to an interdisciplinary team of researchers at the UCLA Jonsson Comprehensive Cancer Center. The thumb-sized patch h
- South Beach Symposium Poised for 18th Miami Conferencehttps://practicaldermatology.com/news/south-beach-symposium-poised-for-18th-miami-conference/2460253/The 18th Annual South Beach Symposium takes place in Miami Beach next month. Organizers say the annual conference boasts an extensive agenda, with in-depth pre-conference offerings, and sessions topics covering the latest and most well-supported knowledge in clinical and aesthetic dermatology. Ro
- Researchers Elucidate Why Some Beta Blockers May Trigger or Exacerbate Psoriasishttps://practicaldermatology.com/news/researchers-elucidate-why-some-beta-blockers-may-trigger-or-exacerbate-psoriasis/2460211/Beta-blockers can trigger or exacerbate psoriasis, and now scientists at the University of Bonn and Freie Universität Berlin may know why. It appears that beta-blockers can interfere with the breakdown of defective cell components. In return, the cells release messengers that trigger immune-